Auvelity is a combination oral of two generics (bupropion & dextromethorphan). The trials have shown that these two chemicals interact in what appears to be a beneficial way by changing the pk/pd.

AUVELITY uses the first new oral mechanism of action in more than 60 years for MDD.1-4 AUVELITY works on the NMDA receptor, an ionotropic glutamate receptor, and on the sigma-1 receptor in the ...

Axsome Therapeutics AXSM incurred an adjusted loss of 97 cents per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.00. The company had incurred a loss ...

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® ...

Auvelity shows growth with $130.1 million annual sales, impressive in a crowded depression treatment market. Axsome's Q4 reveals surging revenues but widened losses due to high R&D and SG&A expenses.

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity ...

Auvelity is supplied as dextromethorphan HBr 45mg/bupropion HCl 105mg extended-release tablets in 30-count bottles. Prior to initiating treatment, blood pressure should be assessed and monitored ...

Auvelity is supplied as dextromethorphan HBr 45mg/bupropion HCl 105mg extended-release tablets in 30-count bottles. The product is expected to be available in the fourth quarter of 2022. References ...

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 ...